Status: current, Defined. Date: 28-Feb 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4696456012 | Levocloperastine fendizoate 7.08 mg/mL oral suspension | en | Synonym | Active | Initial character case insensitive | SNOMED CT core |
| 4696457015 | Product containing precisely levocloperastine fendizoate 7.08 milligram/1 milliliter conventional release oral suspension (clinical drug) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Levocloperastine fendizoate 7.08 mg/mL oral suspension | Is a | Levocloperastine only product in oral dose form | true | Inferred relationship | Some | ||
| Levocloperastine fendizoate 7.08 mg/mL oral suspension | Has manufactured dose form | Oral suspension | true | Inferred relationship | Some | ||
| Levocloperastine fendizoate 7.08 mg/mL oral suspension | Has precise active ingredient | Levocloperastine fendizoate | true | Inferred relationship | Some | 1 | |
| Levocloperastine fendizoate 7.08 mg/mL oral suspension | Has BoSS | Levocloperastine fendizoate | true | Inferred relationship | Some | 1 | |
| Levocloperastine fendizoate 7.08 mg/mL oral suspension | Has concentration strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Levocloperastine fendizoate 7.08 mg/mL oral suspension | Has concentration strength denominator unit | mL | true | Inferred relationship | Some | 1 | |
| Levocloperastine fendizoate 7.08 mg/mL oral suspension | Plays role | Antitussive therapeutic role | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Australian dialect reference set
FHIR